Ridgeback begins enrolment for phase 2 Covid-19 trial of EIDD-2801
Ridgeback Biotherapeutics announces the start of enrollment in a Phase 2 trial of potential COVID-19 treatment EIDD-2801. The new trial will be conducted using the new COVID-19 drug…
Read More...
Read More...